Company / Shareholders' Equity
Esperion Therapeutics, Inc. Shareholders' Equity History
FY2016-FY2025 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest Shareholders' Equity
-$302.0M
FY2025
5-year range
-$455.0M / -$196.9M
FY2021-FY2025
Trend
+22.3%
vs FY2024
Sector context
#206 of 213
Health Care
What the data says
Esperion Therapeutics, Inc. reports negative total equity of -$302M in FY2025. Negative equity can occur when accumulated losses exceed contributed capital, as reported in the balance sheet from the SEC filing.
Based on SEC 10-K filings.
-$302M in FY2025.
Improved from -$455M to -$302M over the past 2 years.
Health Care sector context is included.
Shareholders' Equity over time
Growth rates
- 3-Year CAGR
- -
- 5-Year CAGR
- -
- 10-Year CAGR
- -
Sector benchmark
Bottom 3% in Health CareTop 97% of 213This company -$302.0M Sector average $2.5B
▼
-111.8% below sector average
Key checks
Key Insights
- In FY2025, shareholders' equity increased 22.3% year-over-year.
- Ranks #206 out of 213 companies in the Health Care sector.
- Peak shareholders' equity was recorded in FY2017.
- Lowest shareholders' equity in the period was in FY2023.
Company context
Key Data Points
- Altman Z-Score -1.60 (distress zone, below 1.8 threshold)
- Negative profit margin: -15.6%
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | Shareholders' EquityValue | YoY GrowthYoY |
|---|---|---|
| FY2025 | -$302.0M | +22.3% |
| FY2024 | -$388.7M | +14.6% |
| FY2023 | -$455.0M | -40.5% |
| FY2022 | -$323.8M | -64.4% |
| FY2021 | -$196.9M | -104.9% |
| FY2020 | -$96.1M | -581.9% |
| FY2019 | $19.9M | -74.8% |
| FY2018 | $79.1M | -67.7% |
| FY2017 | $244.7M | +7.0% |
| FY2016 | $228.6M | -20.4% |
As of FY2025 · SEC 10-K · Updated Jul 2, 2026